[{"id":"ba5a9900-5311-4370-977a-05b3928feb30","acronym":"","url":"https://clinicaltrials.gov/study/NCT04847453","created_at":"2021-04-19T12:52:34.348Z","updated_at":"2025-02-25T13:49:06.836Z","phase":"Phase 1","brief_title":"Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis","source_id_and_acronym":"NCT04847453","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2 • MCL1 • BCL2L1 • SDC1 • BAX","pipe":" | ","alterations":" Chr t(11;14)","tags":["BCL2 • MCL1 • BCL2L1 • SDC1 • BAX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Ninlaro (ixazomib) • dexamethasone • Hemady (dexamethasone tablets)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 08/03/2022","start_date":" 08/03/2022","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2025-02-20"},{"id":"a9a958a0-54fc-401f-80e7-fc0331ae93eb","acronym":"MyDRUG","url":"https://clinicaltrials.gov/study/NCT03732703","created_at":"2021-01-18T18:17:27.493Z","updated_at":"2025-02-25T13:18:42.828Z","phase":"Phase 1/2","brief_title":"Myeloma-Developing Regimens Using Genomics (MyDRUG)","source_id_and_acronym":"NCT03732703 - MyDRUG","lead_sponsor":"Multiple Myeloma Research Consortium","biomarkers":" BRAF • SLC1A5","pipe":"","alterations":" ","tags":["BRAF • SLC1A5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Cotellic (cobimetinib) • Verzenio (abemaciclib) • Balversa (erdafitinib) • Xpovio (selinexor) • Ninlaro (ixazomib) • Darzalex (daratumumab) • dexamethasone • Idhifa (enasidenib) • pomalidomide • Blenrep (belantamab mafodotin-blmf) • GDC-0623"],"overall_status":"Completed","enrollment":" Enrollment 103","initiation":"Initiation: 04/01/2019","start_date":" 04/01/2019","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2025-02-14"},{"id":"7f3be9ed-280b-4ee8-a27b-1fa29dec3944","acronym":"","url":"https://clinicaltrials.gov/study/NCT03506373","created_at":"2025-02-25T16:37:04.959Z","updated_at":"2025-02-25T16:37:04.959Z","phase":"Phase 2","brief_title":"Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia","source_id_and_acronym":"NCT03506373","lead_sponsor":"Mayo Clinic","biomarkers":" SDC1","pipe":"","alterations":" ","tags":["SDC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Ninlaro (ixazomib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 08/14/2018","start_date":" 08/14/2018","primary_txt":" Primary completion: 02/06/2023","primary_completion_date":" 02/06/2023","study_txt":" Completion: 03/11/2026","study_completion_date":" 03/11/2026","last_update_posted":"2025-02-07"},{"id":"2aac339a-fbd4-48aa-9c04-5e7a6adc7234","acronym":"NCI-MATCH","url":"https://clinicaltrials.gov/study/NCT02465060","created_at":"2021-01-17T17:15:30.769Z","updated_at":"2025-02-25T16:36:36.993Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","source_id_and_acronym":"NCT02465060 - NCI-MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Pertuvia (pertuzumab biosimilar) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6452","initiation":"Initiation: 08/17/2015","start_date":" 08/17/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"9ce1ae1c-3677-40b4-81f0-ce916a71323c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02633059","created_at":"2025-09-06T20:42:42.259Z","updated_at":"2025-09-06T20:42:42.259Z","phase":"Phase 1/2","brief_title":"Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma","source_id_and_acronym":"NCT02633059","lead_sponsor":"Mayo Clinic","biomarkers":" GDF15","pipe":"","alterations":" ","tags":["GDF15"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ninlaro (ixazomib) • idasanutlin (RG7388)"],"overall_status":"Completed","enrollment":" Enrollment 33","initiation":"Initiation: 12/30/2015","start_date":" 12/30/2015","primary_txt":" Primary completion: 01/31/2021","primary_completion_date":" 01/31/2021","study_txt":" Completion: 11/01/2022","study_completion_date":" 11/01/2022","last_update_posted":"2024-09-12"},{"id":"8c229a43-88ef-4aa6-9cca-dad9d1af3b1b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03457142","created_at":"2021-01-18T17:02:40.865Z","updated_at":"2025-02-25T14:38:10.967Z","phase":"Phase 2","brief_title":"Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy","source_id_and_acronym":"NCT03457142","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" IL6 • CD28 • CD86","pipe":" | ","alterations":" CD28 expression • IL6 expression","tags":["IL6 • CD28 • CD86"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD28 expression • IL6 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ninlaro (ixazomib) • Orencia (abatacept)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 09/11/2018","start_date":" 09/11/2018","primary_txt":" Primary completion: 11/21/2022","primary_completion_date":" 11/21/2022","study_txt":" Completion: 01/11/2025","study_completion_date":" 01/11/2025","last_update_posted":"2024-05-16"},{"id":"71b2abcb-8431-493c-a6af-7ff2db093e87","acronym":"","url":"https://clinicaltrials.gov/study/NCT03399539","created_at":"2021-01-18T16:46:36.555Z","updated_at":"2024-07-02T16:35:16.514Z","phase":"Phase 1","brief_title":"Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma","source_id_and_acronym":"NCT03399539","lead_sponsor":"Mayo Clinic","biomarkers":" BCL2","pipe":" | ","alterations":" Chr t(11;14)","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Ninlaro (ixazomib) • dexamethasone"],"overall_status":"Completed","enrollment":" Enrollment 7","initiation":"Initiation: 05/02/2018","start_date":" 05/02/2018","primary_txt":" Primary completion: 12/20/2021","primary_completion_date":" 12/20/2021","study_txt":" Completion: 02/23/2024","study_completion_date":" 02/23/2024","last_update_posted":"2024-03-04"},{"id":"eb78ca75-84dc-42fc-9d06-f04752556eba","acronym":"NCI-2018-01292","url":"https://clinicaltrials.gov/study/NCT03587662","created_at":"2021-01-18T17:38:43.114Z","updated_at":"2024-07-02T16:35:23.938Z","phase":"Phase 2","brief_title":"Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer","source_id_and_acronym":"NCT03587662 - NCI-2018-01292","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" SMARCB1","pipe":" | ","alterations":" SMARCB1 negative","tags":["SMARCB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SMARCB1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • doxorubicin hydrochloride • Ninlaro (ixazomib) • daunorubicin • liposomal gemcitabine (FF-10832)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/17/2018","start_date":" 08/17/2018","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 01/31/2025","study_completion_date":" 01/31/2025","last_update_posted":"2024-01-10"},{"id":"712d60d7-437e-4110-862c-d16292e6a321","acronym":"","url":"https://clinicaltrials.gov/study/NCT03506360","created_at":"2021-01-18T17:15:42.413Z","updated_at":"2024-07-02T16:35:24.142Z","phase":"Phase 2","brief_title":"Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma","source_id_and_acronym":"NCT03506360","lead_sponsor":"Mayo Clinic","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Ninlaro (ixazomib) • dexamethasone"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 06/19/2018","start_date":" 06/19/2018","primary_txt":" Primary completion: 11/14/2019","primary_completion_date":" 11/14/2019","study_txt":" Completion: 12/10/2020","study_completion_date":" 12/10/2020","last_update_posted":"2024-01-09"},{"id":"6c9623a6-4573-485b-b022-26e539880a69","acronym":"A061202","url":"https://clinicaltrials.gov/study/NCT02004275","created_at":"2021-01-18T09:09:12.624Z","updated_at":"2025-02-25T14:34:26.703Z","phase":"Phase 1/2","brief_title":"Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma","source_id_and_acronym":"NCT02004275 - A061202","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" CYP1A2","pipe":" | ","alterations":" Chr t(14;16) • Chr del(1p)","tags":["CYP1A2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(14;16) • Chr del(1p)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Ninlaro (ixazomib) • dexamethasone • pomalidomide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 118","initiation":"Initiation: 02/01/2014","start_date":" 02/01/2014","primary_txt":" Primary completion: 12/01/2021","primary_completion_date":" 12/01/2021","study_txt":"","study_completion_date":"","last_update_posted":"2023-12-01"},{"id":"a0bd09e4-f67d-438b-b849-d3cd946ef7c2","acronym":"","url":"https://clinicaltrials.gov/study/NCT03616782","created_at":"2021-01-18T17:46:16.289Z","updated_at":"2025-02-25T14:51:05.155Z","phase":"Phase 2","brief_title":"Ixazomib Maintenance in Patients With Newly Diagnosed Mantle Cell Lymphoma(MCL)","source_id_and_acronym":"NCT03616782","lead_sponsor":"Ho Sup Lee","biomarkers":" CD20 • CCND1 • CD5","pipe":" | ","alterations":" Chr t(11;14)","tags":["CD20 • CCND1 • CD5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ninlaro (ixazomib)"],"overall_status":"Recruiting","enrollment":" Enrollment 98","initiation":"Initiation: 12/24/2018","start_date":" 12/24/2018","primary_txt":" Primary completion: 05/31/2026","primary_completion_date":" 05/31/2026","study_txt":" Completion: 05/31/2026","study_completion_date":" 05/31/2026","last_update_posted":"2023-10-06"},{"id":"295b0561-593e-4af2-bcb7-0b0537450f29","acronym":"","url":"https://clinicaltrials.gov/study/NCT03896737","created_at":"2021-01-18T19:11:30.460Z","updated_at":"2024-07-02T16:35:37.895Z","phase":"Phase 2","brief_title":"Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara","source_id_and_acronym":"NCT03896737","lead_sponsor":"European Myeloma Network","biomarkers":" IGH","pipe":" | ","alterations":" IGH translocation","tags":["IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IGH translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • cyclophosphamide • Ninlaro (ixazomib) • Darzalex (daratumumab) • thalidomide • melphalan • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 401","initiation":"Initiation: 04/16/2019","start_date":" 04/16/2019","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2023-09-07"},{"id":"5a1847b9-6a61-4cd7-9d85-f263c78b9445","acronym":"","url":"https://clinicaltrials.gov/study/NCT01936532","created_at":"2022-05-31T02:55:25.156Z","updated_at":"2024-07-02T16:35:41.065Z","phase":"Phase 2","brief_title":"Safety and Efficacy Study of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone in the Initial Management of Multiple Myeloma (IFM2013-06)","source_id_and_acronym":"NCT01936532","lead_sponsor":"Nantes University Hospital","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Ninlaro (ixazomib) • dexamethasone"],"overall_status":"Completed","enrollment":" Enrollment 42","initiation":"Initiation: 11/12/2014","start_date":" 11/12/2014","primary_txt":" Primary completion: 03/01/2019","primary_completion_date":" 03/01/2019","study_txt":" Completion: 06/04/2020","study_completion_date":" 06/04/2020","last_update_posted":"2023-08-03"},{"id":"a29cb757-43e1-4354-ac54-2db07ad38141","acronym":"","url":"https://clinicaltrials.gov/study/NCT02632396","created_at":"2021-01-18T12:48:04.827Z","updated_at":"2025-02-25T14:57:25.287Z","phase":"Phase 1/2","brief_title":"Ixazomib \u0026 Rituximab After Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma in Remission","source_id_and_acronym":"NCT02632396","lead_sponsor":"Emory University","biomarkers":" CCND1","pipe":" | ","alterations":" Chr t(11;14)","tags":["CCND1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Ninlaro (ixazomib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 03/01/2016","start_date":" 03/01/2016","primary_txt":" Primary completion: 08/15/2023","primary_completion_date":" 08/15/2023","study_txt":" Completion: 08/01/2024","study_completion_date":" 08/01/2024","last_update_posted":"2023-05-09"},{"id":"0571b3b6-6285-4835-ab7e-a7fe6fcc54ee","acronym":"","url":"https://clinicaltrials.gov/study/NCT02942095","created_at":"2021-01-18T14:26:45.911Z","updated_at":"2025-02-25T14:50:19.404Z","phase":"Phase 1","brief_title":"Study of Ixazomib and Erlotinib in Solid Tumors","source_id_and_acronym":"NCT02942095","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • EGFR T790M • KRAS G12 • EGFR positive • KRAS G13 • EGFR negative","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR T790M • KRAS G12 • EGFR positive • KRAS G13 • EGFR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • Ninlaro (ixazomib)"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 03/06/2017","start_date":" 03/06/2017","primary_txt":" Primary completion: 12/07/2022","primary_completion_date":" 12/07/2022","study_txt":" Completion: 12/07/2022","study_completion_date":" 12/07/2022","last_update_posted":"2023-04-18"},{"id":"b49f9a71-79b2-4ad4-99ad-e4f72ade1673","acronym":"","url":"https://clinicaltrials.gov/study/NCT05722405","created_at":"2023-02-10T15:00:18.286Z","updated_at":"2024-07-02T16:35:55.821Z","phase":"Phase 4","brief_title":"Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma","source_id_and_acronym":"NCT05722405","lead_sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation • Chr t(4;14) • Chr t(14;16)","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr t(4;14) • Chr t(14;16)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Ninlaro (ixazomib)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 07/01/2022","start_date":" 07/01/2022","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 07/31/2025","study_completion_date":" 07/31/2025","last_update_posted":"2023-02-10"},{"id":"cc091dc8-bab0-4b9b-8651-cd27049d0124","acronym":"BMT CTN 1302","url":"https://clinicaltrials.gov/study/NCT02440464","created_at":"2021-01-18T11:41:28.818Z","updated_at":"2024-07-02T16:35:58.276Z","phase":"Phase 2","brief_title":"Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)","source_id_and_acronym":"NCT02440464 - BMT CTN 1302","lead_sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":" | ","alterations":" Chr t(4;14) • Chr t(14;16) • Chr t(14;20)","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(4;14) • Chr t(14;16) • Chr t(14;20)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • Ninlaro (ixazomib) • melphalan • fludarabine IV"],"overall_status":"Completed","enrollment":" Enrollment 57","initiation":"Initiation: 08/01/2015","start_date":" 08/01/2015","primary_txt":" Primary completion: 10/01/2020","primary_completion_date":" 10/01/2020","study_txt":" Completion: 10/01/2020","study_completion_date":" 10/01/2020","last_update_posted":"2023-01-04"},{"id":"855dd99b-0486-413b-8745-83182704b7d8","acronym":"","url":"https://clinicaltrials.gov/study/NCT02582359","created_at":"2021-01-18T12:31:30.489Z","updated_at":"2025-02-25T14:57:23.823Z","phase":"Phase 1","brief_title":"MLN 9708 in Induction and Consolidation for Adults With AML \u003e= 60 Years of Age","source_id_and_acronym":"NCT02582359","lead_sponsor":"Massachusetts General Hospital","biomarkers":" CD74","pipe":" | ","alterations":" CD74 expression","tags":["CD74"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD74 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Ninlaro (ixazomib) • daunorubicin"],"overall_status":"Completed","enrollment":" Enrollment 39","initiation":"Initiation: 01/01/2016","start_date":" 01/01/2016","primary_txt":" Primary completion: 04/01/2022","primary_completion_date":" 04/01/2022","study_txt":" Completion: 04/01/2022","study_completion_date":" 04/01/2022","last_update_posted":"2022-08-24"},{"id":"cabf613a-e4de-4886-be34-072602ab5414","acronym":"","url":"https://clinicaltrials.gov/study/NCT02042989","created_at":"2021-01-18T09:23:01.961Z","updated_at":"2025-02-25T14:56:53.642Z","phase":"Phase 1","brief_title":"MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies","source_id_and_acronym":"NCT02042989","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ninlaro (ixazomib) • Zolinza (vorinostat)"],"overall_status":"Completed","enrollment":" Enrollment 68","initiation":"Initiation: 06/27/2014","start_date":" 06/27/2014","primary_txt":" Primary completion: 01/22/2020","primary_completion_date":" 01/22/2020","study_txt":" Completion: 01/22/2020","study_completion_date":" 01/22/2020","last_update_posted":"2022-07-11"},{"id":"af2ddd01-c302-4d1b-9b6a-8665f4437f5a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02481310","created_at":"2021-01-18T11:56:55.356Z","updated_at":"2025-02-25T14:57:14.569Z","phase":"Phase 1/2","brief_title":"Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT02481310","lead_sponsor":"Northwestern University","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" MYC rearrangement","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • methotrexate • Ninlaro (ixazomib) • vincristine • prednisone • Novex (rituximab biosimilar) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 10/28/2015","start_date":" 10/28/2015","primary_txt":" Primary completion: 09/26/2020","primary_completion_date":" 09/26/2020","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2022-02-21"},{"id":"7a1dce8c-3c2b-4fe0-a616-9384b398ef55","acronym":"","url":"https://clinicaltrials.gov/study/NCT02169791","created_at":"2021-09-02T22:53:31.329Z","updated_at":"2025-02-25T14:56:58.880Z","phase":"Phase 2","brief_title":"Nonmyeloablative Haploidentical Transplant Followed by MLN9708","source_id_and_acronym":"NCT02169791","lead_sponsor":"Northside Hospital, Inc.","biomarkers":" CD33 • HLA-B","pipe":"","alterations":" ","tags":["CD33 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Ninlaro (ixazomib)"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 07/15/2014","start_date":" 07/15/2014","primary_txt":" Primary completion: 07/28/2020","primary_completion_date":" 07/28/2020","study_txt":" Completion: 07/28/2020","study_completion_date":" 07/28/2020","last_update_posted":"2021-09-02"},{"id":"895fbde3-58eb-4bbb-b7c0-359c9d1de505","acronym":"","url":"https://clinicaltrials.gov/study/NCT02504359","created_at":"2021-01-18T12:05:19.799Z","updated_at":"2024-07-02T16:36:38.273Z","phase":"Phase 1","brief_title":"Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma","source_id_and_acronym":"NCT02504359","lead_sponsor":"OHSU Knight Cancer Institute","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":" | ","alterations":" Chr del(17p)","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(17p)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • etoposide IV • methotrexate • Ninlaro (ixazomib) • carmustine • melphalan • Starasid (cytarabine ocfosfate) • methotrexate IV"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 07/20/2015","start_date":" 07/20/2015","primary_txt":" Primary completion: 09/09/2020","primary_completion_date":" 09/09/2020","study_txt":" Completion: 09/09/2020","study_completion_date":" 09/09/2020","last_update_posted":"2020-11-23"},{"id":"562ebd23-82cd-46f6-9ef4-7d25eaa6ea36","acronym":"","url":"https://clinicaltrials.gov/study/NCT02400437","created_at":"2021-01-18T11:27:12.209Z","updated_at":"2025-02-25T14:57:11.344Z","phase":"Phase 2","brief_title":"Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia","source_id_and_acronym":"NCT02400437","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" MYD88 • CXCR4","pipe":" | ","alterations":" MYD88 L265P • CXCR4 mutation","tags":["MYD88 • CXCR4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYD88 L265P • CXCR4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Ninlaro (ixazomib)"],"overall_status":"Completed","enrollment":" Enrollment 26","initiation":"Initiation: 04/01/2015","start_date":" 04/01/2015","primary_txt":" Primary completion: 11/01/2019","primary_completion_date":" 11/01/2019","study_txt":" Completion: 11/01/2019","study_completion_date":" 11/01/2019","last_update_posted":"2020-09-02"},{"id":"79a35ddc-9a81-40dc-aa01-8f0c2d808459","acronym":"","url":"https://clinicaltrials.gov/study/NCT03856112","created_at":"2021-01-18T19:01:46.510Z","updated_at":"2024-07-02T16:37:01.276Z","phase":"Phase 1/2","brief_title":"Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple Myeloma","source_id_and_acronym":"NCT03856112","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2 • CD4","pipe":"","alterations":" ","tags":["BCL2 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Ninlaro (ixazomib) • dexamethasone"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 06/21/2019","start_date":" 06/21/2019","primary_txt":" Primary completion: 12/31/2021","primary_completion_date":" 12/31/2021","study_txt":" Completion: 12/31/2021","study_completion_date":" 12/31/2021","last_update_posted":"2019-03-26"}]